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Seventy-five small for gestational age (SGA) children were
studied in a randomized, double-blind, dose-response GH trial
with either 1 or 2 mg GH/m2d. Mean (SD) age at the start of GH
therapy was 7.3 (2.2) yr. Data were compared with Dutch ref-
erence data.
In SGA boys, mean (SD) age at onset of puberty was 12.0 (1.0)
and 11.6 (0.7) yr, and in SGA girls it was 10.9 (1.1) and 10.6 (1.2)
yr when treated with 1 and 2 mg GH/m2d, respectively. SGA
boys treated with the lower GH dose started puberty later
than the appropriate for gestational age (AGA) controls; for
the other GH-dosage groups there was no significant differ-
ence in age at onset of puberty compared to AGA controls. The
age at menarche and the interval between breast stage M2 and
menarche were not significantly different for GH-treated SGA
girls compared to their peers. The duration of puberty and
pubertal height gain of GH-treated SGA boys and girls were
not significantly different between the two GH-dosage groups
and were comparable with untreated short children born
SGA.
In conclusion, long-term GH therapy in short SGA children
has no influence on the age at onset and progression of pu-
berty compared to AGA controls, regardless of treatment with
a dose of 1 or 2 mg GH/m2d. Duration of puberty and pubertal
height gain were not significantly different between the GH-
dosage groups. (J Clin Endocrinol Metab 88: 5753–5758, 2003)
SPONTANEOUS POSTNATAL CATCH-UP growth oc-curs in most infants born SGA, but about 10% remain
short after the age of 2 yr (1, 2). Important determinants of
final height are the height and age at onset of puberty and
the magnitude and duration of the pubertal growth (3–5).
Data on puberty in children born SGA are limited. Most
studies deal with height and age at onset of puberty and not
with duration and progression of puberty. Moreover, study
results are difficult to compare due to the various definitions
of SGA and the various definitions used for the milestones
of puberty. Persson et al. (6) reported that children born SGA
were shorter at onset of puberty than their peers but that the
age at onset was the same. A French study reported that the
age at onset of puberty, the age at menarche, and the pubertal
growth spurt in girls born SGA were comparable with the
normal population (7, 8). A Swedish population-based study
showed that in SGA children with a spontaneous catch-up
growth, puberty occurred at the normal age in contrast to
SGA children with persistent short stature who had a slightly
earlier pubertal onset (1). Most authors do seem to agree that
puberty in short SGA children starts at a normal age, but
relatively early for their short stature (9).
Several studies have demonstrated that GH treatment re-
sults in a significant catch-up growth in short prepubertal
SGA children (10, 11). However, only very limited data are
available on puberty and pubertal growth of children born
SGA who have been treated with GH for several years. We
therefore evaluated puberty in terms of age and height at
onset of puberty, age at menarche, interval between breast
development and menarche, duration of puberty, and pu-
bertal height gain in 75 GH-treated children born SGA who
participated in a randomized, double-blind, dose-response
trial, evaluating the effect of a GH dose of either 1 or 2
mg/m2d (0.03 or 0.07 mg/kgd), in comparison to normal-
statured children born appropriate for gestational age
(AGA).
Patients and Methods
Study group
The study group consisted of 75 prepubertal short children born SGA
who met the following criteria at the start of GH treatment: 1) birth
length sd score (SDS) below 2 sd for gestational age according to the
standards of Usher and McLean (12); 2) chronological age between 3 and
11 yr in boys and 3 and 9 yr in girls at the start of the study; 3) height
SDS for chronological age below 2 sd according to Dutch references
(13); 4) height velocity SDS for chronological age no greater than zero
(13, 14), to exclude children with spontaneous catch-up growth; 5) pre-
pubertal stage defined as Tanner breast stage I for girls, and testicular
volume less than 4 ml for boys (15); 6) uncomplicated neonatal period,
that is without signs of severe asphyxia (defined as an Apgar score 3
after 5 min), without sepsis neonatorum and without long-term com-
plications of respiratory ventilation such as bronchopulmonary dyspla-
sia. Exclusion criteria were: endocrine or metabolic disorders, chromo-
somal disorders, growth failure caused by other disorders (emotional
deprivation, severe chronic illness, chondrodysplasia) or syndromes,
and previous or present use of medication that could interfere with GH
treatment. The original group consisted of 79 children. Four children
dropped out of the study before the onset of puberty for the following
reasons. Three children were no longer motivated to inject GH daily after
15, 45, and 51 months of GH treatment, respectively, despite ongoing
catch-up growth with GH treatment. In one prepubertal boy, GH treat-
ment was discontinued after 27 months because of signs of GH insen-
sitivity. Because these four children were lost to follow-up after dis-
continuation of GH, their data were not included in the analysis.
Abbreviations: AGA, Appropriate for gestational age; AH, adult
height; BMI, body mass index; CI, confidence interval; P10, 10th per-
centile; P50, 50th percentile; P90, 90th percentile; RUS, radius, ulna,
short-bones score; SDS, sd score; SGA, small for gestational age; TH,
target height.
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Four centers in The Netherlands participated in the study. The study
was approved by the Ethics Committee of each participating center. Due
to ethical considerations, the Ethics Committees did not allow for a
control group until adult height (AH). Written informed consent was
obtained from the parents or custodians of each child.
Study design
All children were randomly and blindly assigned to one of two
GH-dosage groups: group A received 1 mg GH /m2d, and group B
received 2 mg GH/m2d (0.03 or 0.07 mg/kgd, respectively). Biosyn-
thetic GH (recombinant human GH; Norditropin, Novo Nordisk A/S,
Denmark) was given sc once daily at bedtime with a pen injection
(Nordiject 24). Every 3 months, the total GH dose was adjusted to the
calculated body surface. The study was kept double-blind by using an
equal volume of a reconstituted preparation (10).
Measurements
Height was measured at baseline and subsequently every 3 months,
according to the method of Cameron, using a Harpenden stadiometer
(16). Four measurements were made per visit by the same investigators
(1991–1995, W. d. Waal; 1995–1998, T. Sas; and 1998–2001, Y. v. Pareren),
and the mean was used for the analysis. Height was expressed as SDS
for chronological age (13). Target height (TH) was calculated on the basis
of Dutch reference data with the addition of 3 cm for a secular trend:
for boys, 1⁄2  (Heightfather  Heightmother  12)  3; for girls, 1⁄2 
(Heightfather  Heightmother  12)  3 (13). TH and body mass index
(BMI) were expressed as SDS using Dutch references (13). Bone age was
determined by the same investigators according to Tanner and White-
house radius, ulna, short-bones score (RUS TW-2) (17). AH in GH-
treated children was defined as the condition when height velocity had
dropped less than 0.5 cm during the previous 6 months and the bone age
was at least 15 yr for girls and at least 16.5 yr for boys. AH was reached
either during GH treatment or during the 2-yr follow-up after discon-
tinuation of GH treatment. GH treatment was discontinued after reach-
ing AH or on the patient’s decision at near-AH. At each visit, pubertal
stages were assessed by the same investigators according to the method
of Tanner and Whitehouse (15). The onset of puberty was defined as a
breast development stage 2 according to Tanner scale for girls (15) and
a testicular volume equal or more than 4 ml for boys as determined by
means of a Prader orchidometer. At each 3-monthly visit, girls were
asked if and when they had their menarche. The interval between breast
development (M2) and menarche was defined as the time from onset of
puberty (breast stage 2) until menarche. The pubertal height gain and
the duration of puberty were defined as the AH minus height (centi-
meters) at onset of puberty and the time from onset of puberty until AH,
respectively.
Statistical analyses
The Fourth Dutch National Growth Study (1997) served as reference
for age and height at onset of puberty, age at menarche, and the interval
between M2 and menarche of normal statured children born AGA
(controls) (18). In that study, the same definitions for pubertal milestones
were used as in our study, but because AH was not defined in the Dutch
Growth Study we could not compare our data on duration of puberty
and pubertal height gain with Dutch references. An independent stat-
istician (P.M.) performed the statistical analyses. Data are expressed as
the mean sd, unless indicated otherwise. The null hypothesis of mean
SDS values being equal to zero was tested by the one-sample Student’s
t test. Mean differences of continuous variables between groups were
tested using a Student’s two-sample t test with variances pooled across
all groups. The corresponding 95% confidence interval (CI) was used in
case of no significance in the mean difference. Multiple linear regression
analyses were used to test the influence of several variables on the age
at onset of puberty, interval between M2 and menarche, and pubertal
height gain in GH-treated SGA children. A P value  0.05 was consid-
ered significant. All analyses were performed using SPSS version 10.0
(SPSS, Inc., Chicago, IL).
Results
GH trial
Table 1 lists the baseline clinical data of all 75 children at
start of GH treatment. Both GH-dosage groups had similar
initial characteristics at the start of GH treatment. After the
onset of puberty, three children dropped out of the study:
one girl due to early puberty at the age of 8.4 yr after 27
months of GH treatment, and two other children who were
not motivated despite ongoing GH-induced catch-up
growth. Their data were only included in the analysis of
pubertal onset.
The onset of puberty
Table 2 lists the age, height (SDS), bone age, BMI (SDS),
and duration of GH treatment at the onset of puberty for both
GH-dosage groups compared with Dutch AGA controls.
Mean (sd) age at onset of puberty for boys was 12.0 (1.0) yr
in group A and 11.6 (0.7) yr in group B, and for girls 10.9 (1.1)
yr in group A and 10.6 (1.2) yr in group B, without significant
differences between the two GH-dosage groups. Boys of
group A were significantly older at onset of puberty than the
AGA controls. For girls the age at onset in the GH-dosage
groups vs. the AGA controls was not significantly different.
Mean height SDS at onset of puberty for boys was1.3 (0.7)
in group A and0.9 (0.9) in group B, and for girls1.0 (0.6)
in group A and 0.9 (1.4) in group B, without significant
differences between the two GH-dosage groups. Height SDS
at onset of puberty was significantly lower than for the AGA
controls, for boys and girls.
At onset of puberty, there was a moderately advanced
bone age for boys and girls compared with age, regardless of
GH-dosage group. However, only in boys was bone age
significantly older than chronological age. The BMI SDS in
boys and girls was significantly lower than zero for both
GH-dosage groups without a significant difference between
the two GH-dosage groups. The duration of GH treatment
before the onset of puberty in boys and girls was not sig-
nificantly different between the two GH-dosage groups.
Menarche
The mean age at menarche and the interval between M2
and menarche between the GH-dosage groups and the AGA
controls were not significantly different (Table 3). In addi-
tion, age at menarche and the interval between M2 and
menarche were not significantly different between both GH-
dosage groups.
TABLE 1. Clinical data in 75 children at start of GH treatment
Group A
1 mg/m2d
(n  39)
Group B
2 mg/m2d
(n  36)
Male/female 29/10 21/15
Gestational age (wk) 37.3 (3.2) 36.0 (4.2)
Birth length SDS 3.5 (1.4) 3.5 (1.6)
Birth weight SDS 2.6 (1.2) 2.6 (1.0)
Chronological age (yr) 7.4 (2.0) 7.3 (2.4)
Bone age (RUS; yr) 6.6 (2.5) 6.9 (3.0)
Height SDS 3.0 (0.7) 3.1 (0.7)
Data are expressed as mean (SD).
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The duration of puberty and pubertal height gain
Forty-six children reached AH. Their baseline data were
comparable with those of the 29 SGA children who did not
yet reach AH, with the exception of an older mean age at start
of GH treatment [8.5 (1.7) yr compared with 5.6 (1.7) yr in the
29 SGA children]. The duration of puberty and pubertal
height gain were analyzed for those who reached AH (Table
4). The duration of puberty was not significantly different for
group A and group B in both sexes. The mean (sd) pubertal
height gain for boys was 27.0 (8.4) cm in group A and 31.4
(4.1) cm in group B, in girls 19.0 (7.3) cm in group A and 18.9
(5.7) cm in group B. For boys and girls, mean pubertal height
gain was not significantly different between the two GH-
dosage groups.
Figures 1 and 2 show the 10th percentile (P10), 50th per-
centile (P50), and 90th percentile (P90) ages of reaching the
milestones of puberty for boys and girls, respectively.
Variables
Table 5 shows the results of the multiple regression anal-
ysis regarding the age at onset of puberty, interval between
M2 and menarche, and pubertal height gain.
Variables influencing age at onset of puberty. Boys started their
puberty 1 yr later than girls. The longer the duration of GH
treatment, the older the age at the start of puberty. BMI and
bone age delay at onset of puberty and GH dosage had no
influence on the age at onset.
Variables influencing the interval between M2 and menarche. The
older the age at onset of puberty, the shorter the interval
TABLE 2. Data at onset of puberty in 75 GH-treated SGA children vs. Dutch AGA controls
SGA Difference B  A
(95% CI) AGA controls
a
Group A Group B
Boys
No. 29 21 2524
Age (yr) 12.0 (1.0)b 11.6 (0.7) 0.4 (0.9 to 0.1) 11.5
Height (cm) 144.7 (7.8) 145.2 (6.2) 0.5 (3.7 to 4.6) 151.0
Height SDS 1.3 (0.7)c 0.9 (0.9)c 0.4 (0.0 to 0.9) 0.0
Bone age (RUS yr) 12.4 (2.8) 12.7 (1.2) 0.3 (1.0 to 1.6)
BMI SDS 0.5 (1.3) 0.3 (0.6) 0.2 (0.4 to 0.8)
Duration of GH therapy (yr) 4.3 (2.2) 4.0 (2.5) 0.3 (1.7 to 1.0)
Girls
No. 10 15 2266
Age (yr) 10.9 (1.1) 10.6 (1.2) 0.3 (1.2 to 0.7) 10.7
Height (cm) 141.9 (7.4) 141.5 (10.8) 0.4 (8.5 to 7.7) 147.3
Height SDS 1.0 (0.6)c 0.9 (1.4)c 0.1 (0.7 to 1.0) 0.0
Bone age (RUS yr) 11.3 (1.4) 11.1 (1.6) 0.2 (1.5 to 1.1)
BMI SDS 0.8 (0.9) 0.6 (0.8) 0.2 (0.5 to 0.9)
Duration of GH therapy (yr) 4.0 (1.9) 3.7 (1.8) 0.3 (1.9 to 1.2)
Data are expressed as mean (SD). Groups A and B received 1 and 2 mg GH/m2d, respectively.
a Data of 4th Dutch National Growth Study (18).
b Group A vs. AGA controls, P  0.02.
c SGA groups vs. AGA controls, P  0.05.
TABLE 3. Age at menarche and interval between M2 and menarche in GH-treated SGA girls compared to Dutch AGA controls
SGA
Difference B  A (95% CI) AGA controlsa
Group A Group B
No. 10 13 3028
Age at menarche (yr) 12.9 (0.8) 13.1 (1.3) 0.2 (0.7 to 1.2) 13.2
Interval M23 menarche (yr) 2.0 (0.9) 2.3 (0.9) 0.3 (0.5 to 1.1) 2.5
Data are expressed as mean (SD). Groups A and B received 1 and 2 mg GH/m2d, respectively.
a Data of 4th Dutch National Growth Study (18).
TABLE 4. Pubertal height gain and duration of puberty in 46 GH-treated SGA children who reached AH
Group A
1 mg/m2d
Group B
2 mg/m2d
Difference B  A
(95% CI)
Boys n  14 n  12
Duration of puberty (yr) 5.0 (1.3) 5.4 (0.8) 0.4 (0.5 to 1.3)
Pubertal height gain (cm) 27.0 (8.4) 31.4 (4.1) 4.5 (1.0 to 9.9)
TH SDS 1.0 (0.9) 0.5 (0.7) 0.5 (0.0 to 1.0)
Girls n  9 n  11
Duration of puberty (yr) 3.9 (1.0) 4.1 (1.1) 0.2 (0.8 to 1.2)
Pubertal height gain (cm) 19.0 (7.3) 18.9 (5.7) 0.1 (6.2 to 6.1)
TH SDS 0.7 (0.7) 0.4 (1.1) 0.3 (0.5 to 1.1)
Data are expressed as mean (SD).
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between M2 and menarche. A higher BMI resulted into a
shorter interval, and the greater the bone age delay at onset
of puberty the greater the interval. The GH dosage had no
influence on the interval between M2 and menarche.
Variables influencing pubertal height gain. The difference in
height gain between boys and girls was 13.8 cm. A greater
bone age delay at onset of puberty increased pubertal height
gain, and a taller height and older age at onset of puberty
reduced the pubertal height gain. TH SDS and GH dosage
had no significant effect on pubertal height gain.
Discussion
Our study presents the effects of GH treatment on puberty
in short children born SGA. GH treatment with either 1 or 2
mg/m2d had no effect on pubertal onset, age at menarche,
and interval between M2 and menarche, compared with
Dutch reference data. Also, there was no GH-dose effect on
the duration of puberty and pubertal height gain. Children
with an older age, higher BMI, and smaller bone age delay
at onset of puberty had a shorter interval between M2 and
menarche. Again, the GH dose had no influence. The pu-
bertal height gain was higher in children with a younger age,
shorter height, and a greater bone age delay at onset of
puberty, whereas the GH dose and TH had no effect on the
pubertal height gain.
Our study shows that there is no GH-dose effect on the age
at onset of puberty in SGA children. Also, GH-treated SGA
children did not start puberty at a younger age compared
with normal-statured Dutch children born AGA (18). SGA
boys receiving 1 mg GH /m2d started their puberty even
significantly later than normal-statured Dutch boys born
AGA. Thus, GH treatment does not result into a younger age
at onset of puberty, which is also supported by data of
regression analysis, showing that the longer the duration of
GH treatment, the later the onset of puberty. Both GH-dosage
groups had a similar duration of GH treatment before the
onset of puberty. Bone age delay and BMI had no influence
on the age at onset of puberty. Our study also shows that
SGA boys start their puberty 1 yr later than SGA girls, which
is comparable with the Dutch reference data (18). Compared
with published data of untreated SGA children, we did not
find a significant difference regarding age at onset of puberty
between our GH-treated SGA girls and Swedish untreated
SGA girls (6). Boys receiving 2 mg were 0.8 yr (P  0.01)
younger at onset of puberty than untreated Swedish SGA
boys. However, in this respect it is important to mention that
the definition of onset of puberty in the Swedish study was
different from ours, because their onset of puberty was de-
fined as the moment at which the growth velocity starts to
be more than 6 cm/yr, whereas for our study the onset of
puberty was defined as a testis volume of 4 ml in boys, which
is known to precede the pubertal growth velocity by 1 yr in
boys. This means that when we would have applied the
Swedish definition of puberty on our data set, the onset of
puberty in our group would have been even later. In our
study, we could not use the increase in growth velocity as the
onset of puberty, because we could not determine whether
the increase of height velocity was induced by GH therapy
or pubertal growth spurt or both.
Height at onset of puberty was not significantly different
in both GH-dosage groups, but it was significantly shorter
than the height at pubertal onset of the Dutch normal-stat-
ured AGA children.
Boys had a significantly advanced bone age at onset of
puberty compared with the chronological age in both GH
FIG. 2. Milestones of puberty for girls. P10, P50, and P90 ages of
reaching the milestones of puberty for girls. onset, Onset of puberty;
menarche, age at onset of menarche [n 10 (A), n 13 (B)]; AH, adult
height [n  9 (A), n  11 (B)]; Co, control.
FIG. 1. Milestones of puberty for boys. P10, P50, and P90 ages of
reaching the milestones of puberty for boys. onset, Onset of puberty;
testvol 8, testicular volume of 8 ml [n 28 (A), n 20 (B)]; testvol 12,
testicular volume of 12 ml [n  26 (A), n  20 (B)]; AH, adult height
[n  14 (A), n  12 (B)]; Co, control.
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groups. It is known that the bone maturation in children born
SGA is different from the normal population and not a re-
liable estimation in SGA children (19–22). In addition bone
age assessment by RUS TW-2 generally results in a 1 yr older
bone age compared with Greulich and Pyle and the chro-
nological age (23). Furthermore, it might be that GH treat-
ment resulted in an acceleration of bone age in boys. How-
ever, it appears that the chronological age at onset of puberty
and the progression of pubertal development of the GH-
treated SGA boys and girls were not significantly different
from normal-statured children born AGA.
One of the milestones of puberty in girls is menarche. Our
study shows that the age at menarche and the interval be-
tween M2 and menarche, an indicator for the progression of
puberty in girls, between both GH-dosage groups were not
significantly different and were comparable with the age of
Dutch AGA controls. The age at menarche and the interval
between M2 and menarche were also not significantly dif-
ferent compared with Swedish untreated SGA girls. This
suggests that GH treatment has no influence on the progres-
sion of puberty in girls. An older age, higher BMI, and
smaller bone-age delay, however, resulted in a shorter in-
terval between M2 and menarche. Several studies have
shown that normal-statured AGA girls with an older age at
onset of puberty pass through pubertal stages faster than
early maturers (24–27).
It is interesting that in our study group BMI had no influence
on the age at onset of puberty, but BMI did influence the pro-
gression of puberty and the age of menarche (data not shown).
In the normal population, it is seen that overweight children
mature earlier than nonoverweight children (28). An explana-
tion for why BMI in our study group had no influence on the
age at onset of puberty but only on the age at menarche and
progression of puberty might be that our SGA children were
lean, with a mean BMI (SDS) significantly lower than zero and
that there was only a narrow variation in the BMI (SDS) before
puberty. However, it is known that during puberty body com-
position changes significantly and for that reason might have an
effect on the age of menarche and progression of puberty in our
study group (29). The reason why BMI has influence on the
progression of puberty might be that a higher BMI results in
higher serum leptin, estrogens, insulin, and IGF-I levels (29).
Leptin is thought to be one of the hormonal factors that signals
to the brain at which time the body is ready for sexual matu-
ration and reproduction (30–32). Kiess et al. (30, 33) also re-
ported that leptin is not the primary signal involved in the
initiation of puberty but might act as a permissive signal al-
lowing puberty to proceed when metabolic resources are
sensed to be sufficient. Some studies suggest that insulin and
IGF-I also have an effect on the mechanism of puberty (34, 35).
For future studies, it will be very interesting to evaluate the
influence of leptin, insulin, and IGF-I on the progression of
puberty.
For the endpoint of puberty, we used AH instead of genital
development stage 5 and breast development stage 5 because
we experienced that these pubertal stages were not reliable
endpoints of pubertal growth. The duration of onset of pu-
berty until AH in boys and girls was not significantly dif-
ferent between the GH-dosage groups. We couldn’t compare
the duration of onset of puberty with AH with the Dutch
reference data because AH was not defined in the Dutch
Growth Study. Also, no published data on duration of pu-
berty until AH in SGA were available. Our study shows that
a greater bone age delay at onset of puberty was associated
with a longer duration of puberty until AH, as has been
reported for other conditions (36, 37).
The pubertal height gain, in our study defined as the AH
minus the height at onset of puberty, was not significantly
less in children receiving 1 mg GH/m2d compared with
those receiving 2 mg GH/m2d. The 95% CI of the mean
difference of the pubertal height gain was, however, rather
large for boys and girls, indicating that the GH-dose effect on
mean pubertal height gain might differ in larger patient
groups. The pubertal height gain was less when children
were older or taller at onset of puberty. This has also been
reported in normal-statured children born AGA (3, 26). TH
had no influence on the pubertal height gain. Children with
a smaller bone age delay at onset of puberty had a reduced
pubertal height gain, because the duration of puberty was
also shorter in these children. A French longitudinal study,
using comparable pubertal milestones and AH criteria as we
did, reported a mean (sd) pubertal height gain in untreated
TABLE 5. Multiple regression analysis on age at onset of puberty (yr), interval between M2 and menarche (yr), and pubertal height
gain (cm)
Dependent variable Independent variable Regressioncoefficient SE P
Age at onset of puberty Sex (girls) 1.04 0.24 0.001
Duration GH therapy at onset of puberty (yr) 0.13 0.06 0.02
BMI SDS at onset of puberty 0.02 0.06 ns
Bone age delay at onset of puberty (yr) 0.20 0.12 ns
GH dose 1 vs. 2 mg/m2d 0.25 0.22 ns
Interval M2 3 menarche Age at onset of puberty (yr) 0.52 0.15 0.002
BMI SDS at onset of puberty 0.37 0.11 0.003
Bone age delay at onset of puberty (yr) 0.32 0.14 0.03
GH dose 1 vs. 2 mg/m2d 0.45 0.28 ns
Pubertal height gain Sex (girls) 13.78 1.60 0.001
Bone age delay at onset of puberty (yr) 2.60 0.33 0.001
Height at onset of puberty (cm) 0.38 0.16 0.02
Age at onset of puberty (yr) 2.68 1.17 0.03
TH SDS 1.17 0.78 ns
GH dose 1 vs. 2 mg/m2d 2.25 0.14 ns
ns, Not significant.
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short SGA children of 23.9 (6.1) and 19.8 (4.9) cm for boys and
girls, respectively (38). This indicates that the pubertal height
gain of our GH-treated SGA children was similar or more,
being 27.0 (8.4) cm for group A and 31.4 (4.1) cm for group
B for boys and 19.0 (7.3) cm for group A and 18.9 (5.7) cm for
group B for girls. As our previously published 5-yr data have
shown, most of our SGA children had their GH-induced
catch-up growth during the first 2 yr (10). After 4 yr of GH
treatment, the mean height was within the target range for
both GH-dosage groups. For that reason, it is not surprising
that as both groups entered puberty after at least 4 yr of GH
treatment, children growing within their target range did not
further increase their height SDS during puberty. On the
other hand, because it has been described that discontinu-
ation of GH might lead to catch-down growth in SGA chil-
dren, it seems advisable to continue GH treatment unless
future research would prove otherwise (39).
In conclusion, age at onset of puberty and menarche and
progression of puberty of short children born SGA during
long-term, continuous GH treatment are comparable with
normal-statured AGA children, regardless of a dose of 1 mg
or 2 mg GH/m2d. In addition, the duration of puberty and
the pubertal height gain were not significantly different be-
tween the GH-dosage groups.
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